CSIMarket
 
La Jolla Pharmaceutical Company  (LJPC)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) 4
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company based in San Diego, California. It focuses on the research, development, and commercialization of innovative therapies for life-threatening diseases. It primarily specializes in the field of auto-immune diseases and inflammation.

The company's main product is a drug called GIAPREZA (angiotensin II), which is approved for the treatment of critically ill patients with septic or other distributive shock. GIAPREZA is used to increase blood pressure in these patients who do not respond to conventional treatments.

La Jolla Pharmaceutical Company also has a pipeline of potential future therapies, including LJPC-401 for hereditary hemochromatosis and LJPC-0118 for severe malaria. It consistently invests in research and development to expand its product portfolio and improve patient outcomes.

Overall, La Jolla Pharmaceutical Company is dedicated to making a positive impact in the field of biopharmaceuticals by developing innovative treatments for life-threatening conditions and improving patients' lives.


   Company Address: 201 Jones Road Waltham 2451 MA
   Company Phone Number: 715-3600   Stock Exchange / Ticker: NASDAQ LJPC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Biocardia Inc

Breaking down Biocardia Inc's Fourth Quarter 2023 Effort: Revenue Tumbles



Biocardia Inc, a leading biotechnology company, has witnessed a significant decline in its share price over the past month, while its strategic partner, StemCardia, experienced a modest increase. These developments, combined with the company's recent financial results, have raised questions about the future outlook for Biocardia Inc.
1. Heart Failure as a Global Health Concern:
Heart failure remains a major global health concern, causing high morbidity and mortality rates. Biocardia Inc's aim to revolutionize biotherapeutic delivery in heart failure treatment shows its commitment to addressing this critical challenge. The company's strategic partnership with StemCardia highlights its intent to offer innovative approaches to combat this complex condition.

Acumen Pharmaceuticals Inc

Serious headline: Acumen Pharmaceuticals Inc Reports Revenue of $10.791 Million in Q4 2023, Net Loss Increases to $16.497 Million

2. Financial Performance in the Fourth Quarter and Fiscal Year 2023:
In the financial fourth quarter of 2023, Acumen Pharmaceuticals Inc disclosed a revenue of $10.791 million. However, the company also reported a net loss of $16.497 million, which is larger than the loss of $12.866 million incurred during the same period the previous year. For the entire fiscal year 2023, Acumen Pharmaceuticals Inc announced a loss of $52.37 million and revenue of $10.79 million.
It is important to note that the net loss per share has widened to -$1.08 from the previous fiscal year's -$1.06. However, there has been no significant change in the revenue, which remains at $0.00 million compared to the previous year.

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc Surpasses Expectations with $1.3875 Million in Revenue 2.

The stock market has been buzzing with excitement over the recent performance of Coeptis Therapeutics Holdings Inc. The company has achieved remarkable growth in the fiscal period ending December 31, 2023, reporting an impressive revenue of $1.3875 million. This figure represents a significant increase compared to the previous year's revenue of $0.00.
One of the most noteworthy aspects of Coeptis Therapeutics Holdings Inc's performance is its significant improvement in net deficit. In the same financial reporting period a year ago, the company reported a deficit of $-40.249 million. However, in the fiscal period ending December 31, 2023, Coeptis Therapeutics Holdings Inc managed to reduce its deficit to $-4.024 million. This extraordinary improvement showcases the company's ability to effectively manage its finances and make positive strides towards profitability.

Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc. Faces Mounting Losses in Fourth Quarter Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently made a significant breakthrough in the battle against Type 1 Diabetes Mellitus (T1D). This renowned player in biotech innovation has gained FDA authorization for an expanded access therapy utilizing CELZ-201, a pioneering cell-based program aimed at managing abnormal glucose tolerance and preventing T1D in individuals at high risk.
Type 1 Diabetes Mellitus is a chronic autoimmune condition where the body's immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. This leads to an inability to regulate blood sugar levels and a lifelong dependence on insulin injections. Despite advancements in diabetes management, finding a cure for T1D has remained elusive. However, the revolutionary therapy developed by Creative Medical Technology Holdings holds immense promise in preventing the onset of this debilitating disease.

Valneva Se

Valneva Se Reports $0.82 Loss Per Share in Financial Fourth Quarter of 2023

Valneva Se, a biotechnology and pharmaceutical company, recently reported their financial results for the fourth quarter of 2023. The company experienced a loss of $0.82 per share, an improvement from the $1.39 loss per share in the previous year. However, this was still a significant decrease from the revenue of $404.66 million in the same period a year before, dropping to $172.16 million, a decrease of 57.46%.
Despite the decrease in revenue, Valneva Se was able to reduce their net loss to $113.60 million in the fourth quarter of 2023, compared to a deficit of $160.47 million in the same period the year before. For the full year of 2023, the company reported revenue of $172.16 million.






 

La Jolla Pharmaceutical's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com